comparemela.com

Latest Breaking News On - அறை கிரண்டி மையம் - Page 1 : comparemela.com

NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer s Disease

NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer s Disease
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

NervGen Pharma Corp : NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board

NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease

Bruno Dubois Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; an

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.